Sight Sciences, Inc. Common Stock

Day range

$8.88 – $9.18

Open

$8.97

Prev close

$8.99

Volume

141.11K

Market cap

$495.24M

Shares out

55.09M

P/E

—

P/S

5.94

P/B

9.36

P/FCF

—

ROE

-56.3%

ROA

-28.4%

Debt/Equity

0.77

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeAug 10, 2026

  Additionally, in connection with Mr. Rashid's appointment as Chief Legal Officer and Corporate Secretary, he will be eligible to receive an award of restricted stock units (the "RSU Award") pursuant to the Company's 2021 Incentive Award Plan (the "Plan") with an aggregate value of $1,400,000 subject to the terms and conditions of the Plan and the related award agreement. The RSU Award shall vest in four equal, consecutive annual installments, commencing on August 10, 2027...

• Investor presentationAug 5, 2026

  On August 5, 2026, the Company posted an investor presentation to its website at https://investors.sightsciences.com/. The Company expects to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others.

• Annual meeting resultsJun 5, 2026

  On June 4, 2026, Sight Sciences, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting")... Based on the foregoing votes, Gerhard Burbach and Staffan Encrantz were elected as Class II directors, and the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was duly ratified.

• Investor presentationMay 6, 2026

  On May 6, 2026, the Company posted an investor presentation to its website at https://investors.sightsciences.com/. The Company expects to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others.

• Material litigationApr 23, 2026

  On April 22, 2026, Sight Sciences, Inc. (the "Company") received notification that the U.S. District Court for the District of Delaware (the "Court") entered its final judgment (the "Final Judgment") regarding the patent infringement case (the "Litigation") filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, "Alcon"). The Company had asserted that Alcon's sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company's patents.

Days to cover

4.1

Short interest

1.42M

Avg volume

343.09K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery Procedures
  positiveBenzinga· Sep 9, 2025
• Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
  positiveGlobeNewswire Inc.· Jul 30, 2025
• Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
  positiveGlobeNewswire Inc.· Jul 29, 2025
• Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica
  positiveGlobeNewswire Inc.· Feb 10, 2025
• Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswire
  positiveGlobeNewswire Inc.· Jul 18, 2024